Simplify Logo
Lupin Pharmaceuticals

Lupin Pharmaceuticals

Global pharmaceutical manufacturer and distributor

Associate Director - Corporate Strategy

Full-TimeDeadline 7/28/27
No salary listed
Expert
Bachelor's, Master's
Naples, FL, USA
In Person

Onsite role based in Naples.

About the job

Requirements
  • An MBA or Master's degree in Business, Life Sciences, Public Health, or a related field is required.
  • At least 8 years of cumulative experience in management consulting and/or in-house strategy, corporate development, or business planning within the pharmaceutical or biotechnology industry is required.
  • At least 5 years of experience advising pharmaceutical clients on growth strategies, portfolio strategy, product launches, pipeline prioritization, and biosimilar market assessments is required.
  • Experience with specialty and complex therapeutic areas is required.
  • Experience at a mid-to-large pharmaceutical or biotechnology company supporting C-level initiatives, long-range planning, mergers and acquisitions, licensing, or biosimilar portfolio assessments is required.
  • Ability to synthesize clinical, regulatory, commercial, market access, and financial insights into actionable recommendations that influence enterprise-wide decisions is required.
  • Experience leading cross-functional teams on go-to-market planning, therapeutic-area strategy, biosimilar commercialization strategy, and enterprise transformation is required.
  • Strong business acumen and understanding of the pharmaceutical value chain, including research and development, regulatory pathways for innovator and biosimilar products, medical strategy, market access, and commercialization are required.
  • Understanding of biosimilar market dynamics, including pricing and contracting strategies, payer behavior, interchangeability considerations, and competitive launch sequencing is required.
  • Understanding of specialty market dynamics, including specialist engagement models, complex patient journeys, and access and reimbursement challenges is required.
  • Analytical, problem-solving, and strategic storytelling abilities, including the ability to influence senior executives, are required.
  • Ability to collaborate effectively in matrixed, global environments is required.
  • Proficiency with modern analytics and presentation tools and emerging artificial-intelligence-enabled strategy and insight-generation technologies is required.
Responsibilities
  • Support enterprise-wide and therapeutic-area-specific strategic initiatives across specialty pharmaceuticals and biosimilars, including Respiratory, Neuroscience, and Ophthalmology.
  • Lead strategic analyses related to portfolio prioritization, lifecycle management, indication expansion, and pipeline trade-offs across innovative specialty assets and biosimilar development programs.
  • Develop strategies for biosimilar market entry and sequencing, competitive landscapes and reference-product strategy, pricing and contracting, access considerations, portfolio optimization, and capital allocation.
  • Partner with Research and Development, Medical Affairs, Market Access, Commercial, and Manufacturing to align strategy across clinical development, regulatory pathways, supply considerations, and commercialization models.
  • Support strategy development for launch planning, post-loss-of-exclusivity strategies, and competitive positioning in specialty and biosimilar markets.
  • Partner with the Chief Executive Officer, Executive Leadership Team, and senior functional leaders to deliver project deliverables that inform investment, growth, and risk decisions.
  • Develop executive-ready presentations, board materials, and strategic narratives that translate clinical, regulatory, market access, and financial inputs into recommendations.
  • Help communicate enterprise and therapeutic-area strategies across the organization to support clarity, alignment, and disciplined execution.
Desired Qualifications
  • A top-tier business school background is preferred.
  • A Bachelor's degree in a science-related discipline, such as Biology, Chemistry, or Pharmacology, is preferred.

About the company

Lupin Pharmaceuticals

Lupin Pharmaceuticals

View

Lupin Limited develops and sells branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients across over 100 markets. It brings medicines to patients by designing formulations and APIs, manufacturing at 15 sites, and distributing through a global network, supported by 7 research centers. Its integrated model combines a broad product portfolio with dedicated manufacturing, diagnostics, digital health, and manufacturing services to serve multiple therapeutic areas. Its goal is to improve patient health outcomes by expanding access to high-quality medicines and strengthening its global research, manufacturing, and digital capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Mumbai, India

Founded

1968

Get referred to Lupin Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 FY27 sales rose 33.3% to INR 82,172 million, a company record.
  • Pitolisant, Sugammadex, Eribulin, and Revefenacin approvals broaden 2026 U.S. launch momentum.
  • August 2026 Tenpoint partnership expands ophthalmology revenues across Europe, the UK, and Switzerland.

What critics are saying

  • June 2026 prednisolone eye-drop recall hit 2.53 million bottles over foreign-substance contamination.
  • Ankleshwar received two FDA observations in March 2026, extending Lupin's compliance overhang.
  • Tolvaptan faces Apotex, Teva, and another entrant in September 2026, crushing pricing.

What makes Lupin Pharmaceuticals unique

  • Lupin is building a specialty care moat through VISUfarma and YUVEZZI in Europe.
  • Ranluspec became the only interchangeable ranibizumab biosimilar in U.S. vials and syringes.
  • Q1 FY27 record revenue came from complex launches, biosimilars, and 42% U.S. sales.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

15%

1 year growth

15%

2 year growth

15%
PR Newswire
Aug 20th, 2026
Lupin partners with Tenpoint to bring presbyopia eye drop YUVEZZI to Europe and UK

Lupin's subsidiary VISUfarma has secured exclusive rights to commercialise YUVEZZI, a once-daily presbyopia eye drop, across the EU, UK, Switzerland, Norway, and Iceland through a licensing agreement with Tenpoint Therapeutics' subsidiary Visus Therapeutics. Under the deal, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus will be eligible for regulatory and commercial milestone payments plus tiered royalties based on net sales. YUVEZZI is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. The treatment addresses a condition affecting approximately 2 billion people globally. The partnership strengthens Lupin's vision care franchise following its acquisition of VISUfarma. Tenpoint is advancing US commercialisation and has submitted regulatory applications in the UK, with plans for additional markets worldwide.

PR Newswire
Aug 17th, 2026
Lupin receives US FDA approval for generic Pitolisant tablets

Lupin Limited has received final approval from the US Food and Drug Administration for its generic Pitolisant Tablets in 4.45 mg and 17.8 mg strengths. The FDA approved Lupin's tablets as bioequivalent to Wakix for the indications in the approved labelling. Lupin is a Mumbai-based global pharmaceutical company that distributes products in over 100 markets. The company specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and six research centres globally, employing over 26,000 professionals.

PR Newswire
Jul 30th, 2026
Lupin launches generic Sugammadex injection in US after FDA approval

Lupin Limited has received US FDA approval and launched Sugammadex Injection in the United States. The product is available in two strengths: 200 mg/2 mL and 500 mg/5 mL single-dose vials. Sugammadex Injection is bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and paediatric patients aged 2 years and older undergoing surgery. Lupin is a Mumbai-based pharmaceutical company with products distributed in over 100 markets. The firm specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and 7 research centres globally, employing over 26,000 professionals.

Multibagg AI
Jul 2nd, 2026
Lupin subsidiary to acquire 43.38% stake in Philippines' MPPI for up to $39.6M by May 2026

Lupin Ltd announced its subsidiary Nanomi B.V. will acquire a 43.38% stake in Multicare Pharmaceuticals Philippines Inc for up to $39.6 million in cash, with completion expected by end-May 2026. The deal involves purchasing 11,794,497 shares from existing shareholders to strengthen Lupin's presence in the Philippines. Separately, MPPI executed a buyback of 2,813,811 shares using retained earnings. As Nanomi did not participate, its holding automatically increased from 51% to 56.28%. MPPI reported turnover of PHP 2,096.60 million and net worth of PHP 1,265.50 million as of 31 March 2025. Lupin's shares fell 2.52% in early trade on 2 April following the announcement, trading at ₹2,216.20 on BSE.

PR Newswire
Jun 26th, 2026
Lupin receives tentative US FDA approval for generic Enzalutamide tablets

Lupin Limited has received tentative approval from the US FDA for its Enzalutamide Tablets in 40mg, 80mg, 120mg and 160mg strengths. The 40mg and 80mg versions were approved as bioequivalent to Astellas' Xtandi Tablets. Whilst Xtandi traditionally comes in 40mg and 80mg strengths, Lupin's tentatively approved 120mg and 160mg formulations will offer healthcare providers and patients additional dosing options. The Mumbai-based pharmaceutical company distributes products in over 100 markets globally. Lupin operates 15 manufacturing sites and seven research centres worldwide, employing over 24,000 professionals. The company specialises in branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapy areas including respiratory, cardiovascular and anti-diabetic treatments.